Clinical Trials | May 20, 2022
Motilal Oswal Private Equity (MOPE) invests in Pathkind Diagnostics
A primary investment of Rs 194.4 crore has been made
A primary investment of Rs 194.4 crore has been made
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
This new fund is amongst the largest for the sector in India
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Multiples is the first private equity (PE) investor in the company
Subscribe To Our Newsletter & Stay Updated
